Showing 1781-1790 of 2152 results for "".
- First Atropine Eye Drop to Slow Myopia Progression in Children Approved in Indiahttps://modernod.com/news/first-atropine-eye-drop-to-slow-myopia-progression-in-children-approved-in-india/2482750/Entod Pharmaceuticals announced it has received marketing authorisation from the Central Drugs Standard Control Organisation (CDSCO) for the first 0.05% atropine eye drops (Myatro XL) developed to slow the progression of myopia in children age 6 to 12. This milestone foll
- Andrew Chang Joins BVI Medical as Chief Commercial Officerhttps://modernod.com/news/andrew-chang-joins-bvi-medical-as-chief-commercial-officer/2482735/BVI Medical announced the appointment of Andrew Chang to the newly created role of Chief Commercial Officer. Mr. Chang will lead the company’s global sales, global marketing, and commercial excellence teams and will report directly to President and CEO Shervin Korangy. Mr. Ch
- Oculis Completes Enrollment in Both DIAMOND Phase 3 Trials of OCS-01 in DMEhttps://modernod.com/news/oculis-completes-enrollment-in-both-diamond-phase-3-trials-of-ocs-01-in-dme/2482732/Oculis Holding said it has completed enrollment in both phase 3 DIAMOND-1 and DIAMOND-2 trials of OCS-01 eye drops in DME. The trials are designed as pivotal registration studies to support global marketing applications including NDA submission and approval by t
- Staar Surgical Announces Restructure of Leadershiphttps://modernod.com/news/staar-surgical-announces-restructure-of-leadership/2482705/Staar Surgical announced a series of changes to their leadership structure. These changes come in an effort to better address marketing needs, according to Staar. Warren Foust, Chief Operating Officer, has been promoted to the newly created role of Preside
- Formycon Receives EU Approval for Eylea Biosimilar FYB203 Under the Brand Names Ahzantive and Baiamahttps://modernod.com/news/formycon-receives-eu-approval-for-eylea-biosimilar-fyb203-under-the-brand-names-ahzantive-and-baiama/2482624/Formycon and its licensing partner Klinge Biopharma jointly announce that the European Commission has granted central marketing authorization for FYB203 (aflibercept), a biosimilar to Eylea, under the brand names Ahzantive and Baiama. The app
- National Eye Institute Study Revisits Role of Annexin-V Biomarker in Retinal Cell Degenerationhttps://modernod.com/news/national-eye-institute-study-revisits-role-of-annexin-v-biomarker-in-retinal-cell-degeneration/2482588/Recent findings from a National Eye Institute-led study shed new light on annexin-V, a widely used biomarker to track apoptosis and retinal cell death in eye disease. The study group identified that annexin-V also binds to immune cells, suggesting it may a have a role as a marker for ocular infla
- Celltrion Receives Positive CHMP Opinion for Eylea Biosimilar in the European Unionhttps://modernod.com/news/celltrion-receives-positive-chmp-opinion-for-eylea-biosimilar-in-the-european-union/2482586/Celltrion announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted positive opinions and recommended marketing authorizations for three biosimilar candidates, including Eydenzelt (CT-P42, aflibercept). Eydenzel
- LumiThera Obtains FDA Authorization of Valeda Treatment for Dry AMDhttps://modernod.com/news/lumithera-obtains-fda-authorization-of-valeda-treatment-for-dry-amd/2482525/The FDA has granted authorization to LumiThera allowing the company to market its Valeda Light Delivery System. This approval, made under the De Novo authorization pathway, makes Valeda the first FDA-authorized device to treat vision loss in patients with dry AMD.
- Astellas Withdraws European Application for Avacincaptad Pegol for GAhttps://modernod.com/news/astellas-withdraws-european-application-for-investigational-geographic-atrophy-treatment/2482517/Astellas Pharma announced it is withdrawing its marketing authorization application for avacincaptad pegol (ACP) from the European Medicines Agency (EMA). ACP, an investigational intravitreal treatment designed to inhibit the complement C5 protein, was developed for geographic atrophy (
- Aviceda Completes Enrollment for Phase 2b SIGLEC Study for Geographic Atrophy Treatmenthttps://modernod.com/news/aviceda-completes-enrollment-for-phase-2b-siglec-study-for-geographic-atrophy-treatment/2482456/Aviceda Therapeutics announced the completion of patient enrollment for its phase 2b SIGLEC study. The trial is comparing the safety and efficacy of the company's lead candidate, AVD-104, with avacincaptad pegol (marketed as Izervay) for the treatment of geographic atrophy (GA) secondary to a